

**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1-2. (Canceled)

3. (Withdrawn) The method of claim 1, wherein said compound is GW9662.

4. (Withdrawn) The method of claim 3, wherein said GW9662 is administered in a dose of from about 0.01 mg/kg to about 500 mg/kg of the subject's body weight.

5-11. (Canceled)

12. (Withdrawn) The method of claim 10, wherein said compound is GW9662.

13. (Withdrawn) The method of claim 12, wherein said GW9662 is administered in a dose of from about 0.01 mg/kg to about 500 mg/jkg of the subject's body weight.

14-19. (Canceled)

20. (Currently amended) A method for inhibiting lysophosphatidic acid (LPA)-induced neointima formation, the method comprising administering to a subject one or more inhibitor of LPA-induced PPAR $\gamma$  activation chosen from among the group consisting of diacylglycerol pyrophosphate, ~~serine phosphoric acids, fatty alcohol phosphates, alkyl ether~~ glycerophosphates, monoacylglycerol-diphosphates, and combinations thereof.

21-22. (Canceled)

23. (Currently amended) A method for inhibiting neointima formation associated with atherosclerosis, the method comprising administering to a subject one or more inhibitor of LPA-induced PPAR $\gamma$  activation chosen from among the group consisting of diacylglycerol

pyrophosphate, serine-phosphoric acids, ~~fatty alcohol phosphates~~, alkyl ether

glycerophosphates, monoacylglycerol-diphosphates, and combinations thereof.

24. (Cancelled)